middle.news
How Will Chimeric’s CHM CDH17 Transform Gastric Cancer Treatment?
8:44am on Monday 8th of December, 2025 AEDT
•
Healthcare
Read Story
How Will Chimeric’s CHM CDH17 Transform Gastric Cancer Treatment?
8:44am on Monday 8th of December, 2025 AEDT
Key Points
FDA grants Orphan Drug Designation to CHM CDH17 for gastric cancer
Phase 1/2 trial ongoing with 9 patients treated and 10 enrolled
CHM CDH17 is a novel 3rd generation CAR-T therapy targeting CDH17 biomarker
Orphan status offers tax credits, fee exemptions, and 7 years market exclusivity
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CHM
OPEN ARTICLE